Form 4: Rapport Therapeutics CFO Troy Ignelzi Reports Stock Purchases

Troy Ignelzi, CFO of Rapport Therapeutics, discloses the purchase of common stock in the company.

Summary

• Troy Ignelzi, the Chief Financial Officer of Rapport Therapeutics, filed a Form 4 with the SEC.
• The form reports the purchase of Rapport Therapeutics common stock.
• On March 12, 2025, Ignelzi purchased 9,900 shares at a price of $10.1 per share.
• On March 13, 2025, Ignelzi purchased an additional 100 shares at $9.98 per share.
• Following these transactions, Ignelzi directly owns 10,000 shares of Rapport Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the purchase is relatively small and may not be highly significant.

Positives

• The CFO's purchase of company stock could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may view the CFO's stock purchase as a positive sign of confidence in the company's future.

Key Dates